# OnCo record irae-neurological (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-neurological/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-neurological" ;
  schema:name "Neurological side effects of checkpoint inhibitors: myasthenia gravis, Guillain-Barré syndrome, meningitis and encephalitis"@en ;
  schema:alternateName "neurologic irAEs"@en, "irAE-N"@en, "checkpoint inhibitor myasthenia gravis"@en, "immune-related Guillain-Barré syndrome"@en, "checkpoint inhibitor encephalitis"@en, "immune-related aseptic meningitis"@en, "immune-related neuropathy"@en ;
  schema:description "Immunotherapy rarely inflames the nerves, the brain or the junction between nerve and muscle. Drooping eyelids, double vision, trouble swallowing or speaking, weakness spreading up the legs, numbness, severe headache with a stiff neck, confusion or a seizure need urgent assessment. Treatment is quick high-dose steroids, often with immunoglobulin or plasma exchange, and a neurologist."@en ;
  schema:url <https://onco.cc/protocols/irae-neurological/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "acute-oncology", "neurology" ;
  onco:related <https://onco.cc/protocols/irae-myocarditis/>, <https://onco.cc/protocols/irae-hypophysitis-adrenal/>, <https://onco.cc/protocols/irae-ocular/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/methylprednisolone/>, <https://onco.cc/drugs/human-normal-immunoglobulin/>, <https://onco.cc/drugs/rituximab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .